CanSino Biologics Inc. announced that the Company has initiated the enrollment of a phase III clinical trial for the 13-Valent pneumococcal polysaccharide conjugate vaccine (CRM197, TT) (the "PCV13i ") developed by the Company. The Company has made improvements in the conjugate design and manufacturing processes of its PCV13i candidate based on its proprietary conjugate vaccine manufacturing know-how. The Company received the approval of clinical trial application for the PCV13i from the National Medical Products Administration of China in April 2019 and has completed the phase I clinical trial in 2020.